Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs
G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.
Projectdetails
Introduction
Congenital Heart Disease (CHD) results when the heart abnormally develops before birth. With diminished cardiac function, the heart fails to supply the required oxygenated blood to the body, causing a cascade of failures at different scales that prevent the newborn from growing normally. Even with improved surgical and medical treatments, CHD remains a lifelong risk factor for many diseases.
Emerging Applications
An emerging application in cardiac tissue engineering is the 3D bioprinting of human hearts, or their parts, for clinical transplantation, with CHD representing a potential therapeutic target.
Current Challenges
Whereas the fabrication of bioartificial hearts is currently feasible, there remain significant scientific and technological challenges that yet need to be overcome. The development of novel experimental approaches is fundamental.
Need for Computational Methods
At the same time, there is a pressing need for complementary computational methods to efficiently assist in the design of biophysically feasible and printable hearts, which must necessarily grow with the CHD patient's body while adapting to lifelong changes in hemodynamic conditions.
Project Objectives
In this project, therefore, I will develop a highly novel and interrelated experimental and computational approach for reproducing and predicting growing conditions of bioengineered hearts.
Experimental Design
The ambitious experimental design will enhance the maturation of cardiac muscle and biomechanical function of bioprinted ventricles in dynamic bioreactors.
Computational Platform
The highly-coupled multi-physics computational platform will describe these complex processes under multiple stimulated conditions to, ultimately, predict the critical adaptation and evolution of bioengineered ventricles potentially implanted in CHD patients.
Conclusion
Therefore, by integrating ground-breaking methods within an extremely complex scenario, G-CYBERHEART will cross boundaries to drive advances in regenerative medicine and tissue engineering that will help accelerate the development of the bioengineered heart of the future.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.497.351 |
Totale projectbegroting | € 1.497.351 |
Tijdlijn
Startdatum | 1-9-2022 |
Einddatum | 31-8-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITAT POLITECNICA DE VALENCIApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughputHEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments. | ERC Consolid... | € 2.969.219 | 2022 | Details |
Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular DiseaseThe 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health. | ERC Starting... | € 1.496.395 | 2022 | Details |
Using CARDIac simulations to run in-silicO clinical TRIALSThis project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials. | ERC Starting... | € 1.499.423 | 2022 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughput
HEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments.
Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease
The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.
Using CARDIac simulations to run in-silicO clinical TRIALS
This project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
High-throughput ultrasound-based volumetric 3D printing for tissue engineeringSONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research. | EIC Pathfinder | € 2.999.625 | 2025 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research. | EIC Pathfinder | € 1.225.468 | 2024 | Details |
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgansTHOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants. | EIC Pathfinder | € 3.994.150 | 2023 | Details |
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
High-throughput ultrasound-based volumetric 3D printing for tissue engineering
SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.
Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research.
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans
THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.